YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling in Prediction of Pediatric Pharmacokinetics

생리학 기반 약물동태(PBPK, Physiologically Based Pharmacokinetic) 모델링을 이용한 소아 약물 동태 예측 연구

  • Received : 2015.01.21
  • Accepted : 2015.02.27
  • Published : 2015.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

In recent years, physiologically based pharmacokinetic (PBPK) modeling has been widely used in pharmaceutical industries as well as regulatory health authorities for drug discovery and development. Several application areas of PBPK have been introduced so far including drug-drug interaction prediction, transporter-mediated interaction prediction, and pediatric PK prediction. The purpose of this review is to introduce PBPK and illustrates one of its application areas, particularly pediatric PK prediction by utilizing existing adult PK data and in vitro data. The evaluation of the initial PBPK for adult was done by comparing with experimental PK profiles and the scaling from adult to pediatric was conducted using age-related changes in size such as tissue compartments, and protein binding etc. Sotalol and lorazepam were selected in this review as model drugs for this purpose and were re-evaluated using the PBPK models by GastroPlus$^{(R)}$. The challenges and strategies of PBPK models using adult PK data as well as appropriate in vitro assay data for extrapolating pediatric PK at various ages were also discussed in this paper.

Keywords

References

  1. Teorell, T. : Kinetics of distribution of substances administered to the body I : The extravascular modes of administration. Arch. Int. Pharmacodyn. Ther. 57, 205 (1937).
  2. Malcolm, R., Carl, P. and Geoffrey. T. : Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45 (2011). https://doi.org/10.1146/annurev-pharmtox-010510-100540
  3. Hannah, M. J., Maurice, D., Kuresh, Y., James, R. G., Neil, J. A., Tanya, L. H., Ian, K. G., Raj, L., Peter, J. B., Barry, C. J. and Iain, B. G. : Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica. 42, 94 (2012). https://doi.org/10.3109/00498254.2011.627477
  4. Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M. and Hall, S. : Physiologically based pharmacokinetic modelling in drug discovery and development : A pharmaceutical industry perspective. Clin. Pharmacol. Ther. 97, 3 (2015).
  5. Jones, H. and Rowland, Y. K. : Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013). https://doi.org/10.1038/psp.2013.41
  6. 윤휘열, 백인환, 서정원, 배경진, 이만형, 강원구, 권광일 : 모델 기반학적 신약개발에서 약동/약력학 모델링 및 시뮬레이션의 역할. Korean J. Clin. Pharm. 18, 84 (2008).
  7. 이상민, 최보윤, 윤휘열, 전다혜, 김명규, 하지혜, 김영훈, 지은희, 강원구, 한나영 : 효율적인 의약품 평가를 위한 약물계량학 분석법 도입의 전략 방안. Korean J. Clin. Pharm. 21, 339 (2011).
  8. GastroPlus http://www.simulations?plus.com/Products.aspx?grpID=3&cID=16&pID=11 (Accessed2013).
  9. Rodgers, T. and Rowland, M. : Physiologically based pharmacokinetic modelling 2 : predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238 (2006). https://doi.org/10.1002/jps.20502
  10. Khalil, F. and Laer, S. : Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-Sotalol as a model drug. AAPS J. 16, 226 (2014). https://doi.org/10.1208/s12248-013-9555-6
  11. Siladitya, R. C., Viera, L. and Walter, S. W. : Modeling disposition of sotalol following Intravenous and oral administration in healthy adult subjects. Abstract #T3075, AAPS Annual Meeting and Exposition. October 23-27 Washington Convention Center, Washington, D.C. (2011).
  12. Poirier, J. M., Jaillon, P., Lecocq, B., Lecocq, V., Ferry, A. and Cheymol, G. : The pharmacokinetics of d-sotalol and d, lsotalol in healthy volunteers. Eur. J. Clin. Pharmacol. 38, 579 (1990). https://doi.org/10.1007/BF00278585
  13. James, J. H. : Clinical pharmacokinetics of sotalol. Am. J. Cardiol. 72, 19a (1993). https://doi.org/10.1016/0002-9149(93)90021-4
  14. Deneer, V. H., Lie, A. H. L., Kingma, J. H., Proost, J. H., Kelder, J. C. and Brouwers, J. R. : Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. Br. J. Clin. Pharmacol. 45, 485(1998).
  15. Tjandramaga, T. B., Verbeeck, R., Thomas, J., Verbesselt, R., Verberckmoes, R. and Schepper, P. J. : The effect of end?stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br. J. Clin. Pharmacol. 3, 259 (1976). https://doi.org/10.1111/j.1365-2125.1976.tb00601.x
  16. Laer, S., Elshoff, J. P., Meibohm, B., Weil, J., Mir, T. S., Zhang, W. and Hulpke, W. M. : Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J. Am. Coll. Cardiol. 46, 1322 (2005). https://doi.org/10.1016/j.jacc.2005.06.061
  17. Egan, J. M. and Abernethy, D. R. : Lorazepam analysis using liquid chromatography : improved sensitivity for single-dose pharmacokinetic studies. J. Chromatogr. 380, 196 (1986). https://doi.org/10.1016/S0378-4347(00)83643-9
  18. Greenblatt, D. J., Comer, W. H., Elliott, H. W., Shader, R. I., Knowles, J. A. and Ruelius, H. W. : Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results. J. Clin. Pharmacol. 17, 490 (1977). https://doi.org/10.1002/j.1552-4604.1977.tb05641.x
  19. Muchohi, S. N., Obiero, K., Newton, C. R., Ogutu, B. R., Edwards, G. and Kokwaro, G. O. : Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. Br. J. Clin. Pharmacol. 65, 12 (2008). https://doi.org/10.1111/j.1365-2125.2007.02966.x
  20. Chamberlain, J. M., Capparelli, E. V., Brown, K. M., Vance, C. W., Lillis, K., Mahajan, P., Lichenstein, R., Stanley, R. M., Davis, C. O., Gordon, S., Baren, J. M. and van den Anker, J. N. : Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. J. Pediatr. 160, 667 (2012). https://doi.org/10.1016/j.jpeds.2011.09.048
  21. Maharaj, A. R., Barrett, J. S. and Edginton, A. N. : A workflow example of PBPK modeling to support pediatric research and development : case study with lorazepam. AAPS J. 15, 455 (2013). https://doi.org/10.1208/s12248-013-9451-0
  22. Yang, Y., Faustino, P. J., Volpe, D. A., Ellison, C. D., Lyon, R. C. and Yu, L. X. : Biopharmaceutics classification of selected ${\beta}$- blockers : Solubility and permeability class membership. Mol. Pharm. 4, 608 (2007). https://doi.org/10.1021/mp070028i
  23. Dahan, A., Miller, J. M., Hilfinger, J. M., Yamashita, S., Yu, L. X., Lennernas, H. and Amidon, G. L. : High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol. Pharm. 7, 1827 (2010). https://doi.org/10.1021/mp100175a
  24. Andrea, N. Edginton and Nikoletta, Fotaki : Oral drug absorption in pediatric populations, Oral drug absorption : prediction and assessment. 2nd ed. New York : Informa healthcare, 108 (2010).
  25. Fernandez, E., Perez, R., Hernandez, A., Tejada, P., Arteta, M. and Ramos, J. T. : Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 3, 53 (2011). https://doi.org/10.3390/pharmaceutics3010053
  26. Zhao, P., Rowland, M. and Huang, S. M. : Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92, 17 (2012). https://doi.org/10.1038/clpt.2012.68
  27. DrugBank http://www.drugbank.ca/drugs/DB00186 (Accessed 2013-09-16).